Publications by authors named "Ferah Aydin"
Article Synopsis
- The study aimed to evaluate the safety and effectiveness of growth hormone (GH) replacement therapy in adults with Langerhans cell histiocytosis (LCH) who also have growth hormone deficiency (GHD), using data from the Pfizer International Metabolic Database (KIMS).
- Out of 81 patients analyzed, one year of GH treatment showed improvements in metabolic parameters like reduced total cholesterol and increased quality of life scores, with 37 patients providing follow-up data.
- The safety analysis revealed 36 serious adverse events over 435 patient-years, but no new safety concerns were identified, suggesting that GH treatment is safe and effective for this population.
Response to GH Treatment After Radiation Therapy Depends on Location of Irradiation.
J Clin Endocrinol Metab
October 2020
Article Synopsis
- Cancer survivors with growth hormone deficiency (GHD) receive growth hormone therapy (GHT) after being monitored for at least a year to ensure their tumor status is stable.
- The study investigates how different types and locations of radiation therapy (RT) impact patients' growth responses to GHT.
- Findings reveal that leukemia patients who underwent total body irradiation (TBI) experienced the least growth response, while those with craniopharyngioma showed the best growth response, indicating varying effects of RT on GHT efficacy.
Article Synopsis
- Children born prematurely and treated with growth hormone (GH) showed a significant increase in height during the early years of treatment.
- A study of 586 preterm children analyzed the effects of GH on near-adult height (NAH), revealing that those born appropriate for gestational age (AGA) had a better growth response than those born small for gestational age (SGA).
- The findings suggest that GH treatment is beneficial, especially in prepubertal children, and that parental height is a strong predictor of growth outcomes, with prematurity not impacting the overall growth response.
Objective: Clinical observations over time of adults with growth hormone (GH) deficiency (GHD) have indicated a shift in patient characteristics at diagnosis. The objective of this study was to compare baseline characteristics of patients diagnosed with adult-onset GHD naive to GH replacement during three study periods (1994-1999 (P1), 2000-2004 (P2), and 2005-2012 (P3)) using the KIMS (Pfizer's International Metabolic) database.
Methods: Data were retrieved for a total of 6069 patients with adult-onset GHD from six countries (Belgium, Germany, Netherlands, Spain, Sweden, and UK): P1 (n = 1705), P2 (n = 2397), and P3 (n = 1967).
Article Synopsis
- The study aimed to investigate how spontaneous versus induced puberty and the type of estrogen treatment affect the height of girls with Turner syndrome undergoing growth hormone (GH) therapy.
- Researchers analyzed data from 772 girls, comparing those who experienced spontaneous puberty (145 girls) with those who required estrogen induction (627 girls).
- The findings indicated that girls with spontaneous puberty showed slightly better growth in response to GH, leading to earlier adult height, but overall height differences between the two groups were not significant at maturity.
Secular Trends on Birth Parameters, Growth, and Pubertal Timing in Girls with Turner Syndrome.
Front Endocrinol (Lausanne)
February 2018
Background: Whether children with chromosomal disorders of growth and puberty are affected by secular trends (STs) as observed in the general population remains unanswered, but this question has relevance for expectations of spontaneous development and treatment responses.
Objectives: The aim of the study was to evaluate STs in birth parameters, growth, and pubertal development in girls with Turner syndrome (TS).
Study Design: Retrospective analysis of KIGS data (Pfizer International Growth Database).
Pegvisomant monotherapy is effective and safe in treatment of acromegaly. However, some clinicians combine pegvisomant with somatostatin analogues (SSA) or dopamine agonist (DA). In this analysis of ACROSTUDY, a long-term non-interventional study, the use of combination regimens was evaluated.
View Article and Find Full Text PDFBackground: Growth prediction models (GPMs) exist to support clinical management of children treated with growth hormone (GH) for growth hormone deficiency (GHD), Turner syndrome (TS) and for short children born small for gestational age (SGA). Currently, no prediction system has been widely adopted.
Content: The objective was to develop a stand-alone web-based system to enable the widespread use of an 'individualised growth response optimisation' (iGRO) tool across European endocrinology clinics.
Background: Children receiving stimulants for attention deficit hyperactivity disorder (ADHD) frequently present to pediatric endocrinology clinics for evaluation and treatment of growth disorders. The worldwide prevalence of stimulant use in children with ADHD also receiving recombinant human growth hormone (rhGH) and the impact on response to rhGH are unknown.
Methods: Data on children enrolled in the KIGS® (Pfizer International Growth Study) registry were evaluated for the associated diagnosis of ADHD prior to initiation of Genotropin® rhGH.